2024-11-13 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Analysis Report

**Company Overview:** Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on developing and commercializing therapies for serious diseases.

**Performance Analysis:**

**1. Return Comparison:**

* **VRTX Cumulative Return:** 183.06%
* **S&P 500 (VOO) Cumulative Return:** 179.25%
* **Return Difference:** 3.81%
* **Relative Difference:** 61.91% (This means VRTX's performance is currently in the 61.91 percentile of its historical performance range against the S&P 500).

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|-------|------|-------|
| 2015-2017  | 21.8% | 40.8% | -16.6% | 1.6 | 38.6 |
| 2016-2018  | 34.8% | 35.1% | 2.5% | 1.5 | 42.7 |
| 2017-2019  | 192.4% | 19.3% | 140.7% | 1.2 | 56.4 |
| 2018-2020  | 54.6% | 30.3% | 7.2% | 0.9 | 60.9 |
| 2019-2021  | 33.8% | 37.4% | -66.2% | 0.8 | 56.5 |
| 2020-2022  | 31.6% | 37.4% | 8.0% | 0.7 | 74.4 |
| 2021-2023  | 77.3% | 23.4% | 42.4% | 0.6 | 104.8 |
| 2022-2024  | 120.2% | 17.2% | 89.8% | 0.6 | 129.2 |

* **CAGR:** Shows the average annual return over a specified period.
* **MDD:** Measures the maximum drawdown or loss experienced during the period.
* **Alpha:** Measures the excess return of the stock compared to the market (positive alpha indicates outperformance).
* **Beta:** Measures the volatility of the stock compared to the market (beta > 1 indicates higher volatility).
* **Cap(B):** Represents the company's market capitalization in billions.

**2. Recent Price Movements:**

* **Closing Price:** 490.0
* **5-day Moving Average:** 500.91
* **20-day Moving Average:** 484.39
* **60-day Moving Average:** 477.38

**3. Technical Indicators:**

* **RSI:** 59.04 (Neutral, indicating neither overbought nor oversold conditions)
* **PPO:** 0.46 (Positive, indicating potential upward momentum)
* **Delta_Previous_Relative_Divergence:** -2.92 (Negative, short-term bearish signal, suggesting potential for a slight decline)
* **Expected Return:** 2.87% (Long-term potential for outperformance compared to S&P 500)

**4. Recent Earnings and Outlook:**

| Date       | EPS    | Revenue |
|------------|-------|---------|
| 2024-11-05 | 4.05   | 2.77 B$ |
| 2024-08-02 | -13.92 | 2.65 B$ |
| 2024-05-07 | 4.26   | 2.69 B$ |
| 2023-11-07 | 4.01   | 2.48 B$ |
| 2024-11-05 | 4.01   | 2.48 B$ |

* The most recent earnings (2024-11-05) showed a significant positive EPS surprise, beating analyst expectations. This may indicate strong performance and positive outlook.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter     | Revenue  | Profit Margin |
|------------|---------|--------------|
| 2024-09-30 | $2.77B  | 85.84%        |
| 2024-06-30 | $2.65B  | 85.94%        |
| 2024-03-31 | $2.69B  | 87.27%        |
| 2023-12-31 | $2.52B  | 85.38%        |
| 2023-09-30 | $2.48B  | 87.17%        |

* Vertex demonstrates consistent revenue growth and high profitability margins, indicating strong financial health.

**2) Capital and Profitability:**

| Quarter     | Equity     | ROE       |
|------------|-----------|-----------|
| 2024-09-30 | $15.63B   | 6.69%     |
| 2024-06-30 | $14.77B   | -24.32%   |
| 2024-03-31 | $18.55B   | 5.93%     |
| 2023-12-31 | $17.58B   | 5.51%     |
| 2023-09-30 | $16.51B   | 6.27%     |

* Vertex maintains a robust equity base with fluctuating ROE, potentially indicating various factors influencing profitability over the past quarters. 

**6. News and Recent Issues:**

* **Recent Earnings News:** 
    * Vertex reported strong Q3 2024 earnings, beating analyst expectations for both EPS and revenue. The company's strong performance was attributed to its leading cystic fibrosis treatments and the expansion of its portfolio.
    * **Analyst Opinions and Performance Highlights:**
    * Analysts are generally positive on VRTX's prospects, with many analysts maintaining buy ratings and optimistic price targets. 
    * Vertex has been a consistent performer in the biotechnology sector, demonstrating strong growth and profitability.

**7. Summary:**

Vertex Pharmaceuticals Inc. is a financially strong biotechnology company with a leading position in the cystic fibrosis treatment market. Recent earnings reports show strong growth and profitability, supported by solid financial metrics. Although the stock exhibits some short-term bearish signals, its long-term prospects remain promising, potentially offering substantial returns compared to the broader market. VRTX is a potentially appealing investment opportunity for investors seeking exposure to the biotechnology sector, particularly those with a long-term investment horizon. 
